Rabia Sakarya

Konya Training and Research Hospital, Conia, Konya, Turkey

Are you Rabia Sakarya?

Claim your profile

Publications (26)32.75 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Purpose: The aim of the present study was to evaluate the effectiveness of topically applied tigecycline for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in a rabbit model. Methods: Experimental bacterial keratitis was induced in rabbits by a corneal intrastromal injection of 100 colony-forming units (CFUs) of MRSA bacteria. Sixteen hours after the injection, 28 rabbits were randomly divided into 4 treatment groups of 7 rabbits each. In each group, the rabbits' eyes were treated topically with 19 doses of topical tigecycline (10 or 50 mg/mL), vancomycin (50 mg/mL), or isotonic saline. Slit lamp examinations were performed before and after the inoculation by two observers masked to the study for the determination of clinical severity. Corneas were harvested for bacterial quantitation and histopathologic examination. Results: No significant differences were observed in the clinical scores between pretreatment and posttreatment in the 4 groups (P>0.05). The mean difference between the pretreatment and posttreatment clinical scores from the 4 treatment groups was also not significant (P>0.05). All treatment groups had significantly lower CFUs compared with the control group. There were no significant differences in the bacterial load among the treatment groups. The minimum inhibitory concentration (MIC) for tigecycline was 0.12 μg/mL, whereas the MIC for vancomycin was 2.2 μg/mL. The tigecycline 10 mg/mL group had the lowest mean epithelial erosion values among the treatment groups. Conclusions: Topical tigecycline significantly reduced the bacterial load in infected rabbit corneas and may be as effective as vancomycin for the topical treatment of MRSA keratitis.
    10/2014;
  • Sertan Goktas, Yasar Sakarya, Rabia Sakarya
    Jama Ophthalmology 09/2014; · 3.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to evaluate the ocular distribution of intravenously administered tigecycline in a rabbit uveitis model.
    08/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Purpose: To investigate the elimination rate of daptomycin after intravitreal injection in uveitis-induced rabbits. Materials and methods: Intravitreal injection of the single dose of 200 μg/0.05 mL daptomycin was administered to rabbits starting 24 h after induction of uveitis by an intravitreal endotoxin injection. Aqueous humor and vitreous humor samples of eight eyes per time point were collected at selected time intervals (1, 3, 6, 24, 48, 72 and 96 h), and the in vitreous half-life was calculated. Daptomycin concentrations in vitreous and aqueous humor were assayed with high-performance liquid chromatography. Results: The vitreous concentration was noted to decline slowly with time. The mean vitreous concentration was 23.25 ± 10.99 μg/mL and 11.10 ± 3.33 μg/mL at 96 h in inflamed and normal eyes, respectively. The vitreous daptomycin concentration showed an exponential decay with a half-life of 25.67 h in normal eyes and 34.6 h in inflamed eyes. The aqueous levels of daptomycin in normal eyes were low but remained significantly higher than those of inflamed eyes. Conclusions: Given that the injected dose corresponds to several times the minimum inhibitory concentrations of organisms most involved in endophthalmitis, and that therapeutic levels are present up to 96 h after injection, intravitreal daptomycin should be considered for the treatment of endophthalmitis caused by Gram-positive bacteria.
    Current eye research. 08/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Purpose: The purpose of this study was to evaluate the ocular distribution of intravenously administered colistin in a rabbit uveitis model. Methods: Colistin, a polypeptide antibiotic against the multidrug-resistant (MDR) Gram-negative organisms, was given intravenously to rabbits at 5 mg/kg of body weight starting 24 h after induction of uveitis by intravitreal endotoxin injection. Colistin concentrations were determined by high-performance liquid chromatography-mass spectrometry assay in the aqueous humor, vitreous humor, and plasma 0.5, 3, 6, and 24 h after administration of a single dose. Results: The maximum colistin concentrations (mean±standard deviation) were found 0.5 h after the end of the intravenous administration and were 9.48±2.0 μg/mL in plasma and 0.62±0.07 μg/mL in the aqueous humor of the inflamed eye. After 24 h, no drug was detectable in the aqueous of the inflamed eyes. Colistin was undetectable in the aqueous of contralateral normal eyes at all time points. Drug concentrations in all the vitreous samples from both inflamed and normal eyes were undetectable, except at the 3-h inflamed eye group, and a colistin concentration of 0.02±0.01 μg/mL was found. Plasma levels of colistin fell to 0.93±0.07 and 0.24±0.08 μg/mL, after 3 and 6 h, respectively, and were not detectable 24 h after the given dose. Conclusions: In our model, colistin did not reach therapeutically relevant levels in the aqueous and in the vitreous humor of rabbit eyes. The findings suggest a limited role for intravenously administered colistin in the treatment of Gram-negative bacterial endophthalmitis.
    07/2014;
  • Arquivos brasileiros de oftalmologia. 06/2014; 77(3):148-151.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the frequency of choroidal abnormalities in pediatric patients with neurofibromatosis type 1 detected by infrared reflectance imaging.
    Journal of pediatric ophthalmology and strabismus. 05/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: PurposeTo measure choroidal thickness in patients with pseudoexfoliation (PEX) syndrome and to compare the values with control eyes using enhanced depth imaging optical coherence tomography (EDI-OCT).Methods Thirty-four patients with PEX syndrome and 30 age- and sex-matched healthy subjects were included in this study. Only one eye of each of the patients was included. Choroidal thickness was measured manually from the outer border of the retinal pigment epithelium to the inner scleral border at the subfovea, 3 mm temporal to the fovea, and 3 mm nasal to the fovea using EDI-OCT.ResultsA total of 34 eyes from 34 consecutive patients with PEX syndrome (19 women and 15 men; mean age 75.3 ± 6.6 years) were included in the analysis. The mean subfoveal, temporal, and nasal choroidal thickness was significantly thinner in the PEX syndrome group compared with the control group (p<0.05, at all points). The mean choroidal thickness in the PEX syndrome group was as follows: 259 ± 33 µm, 211 ± 29 µm, and 106 ± 24 µm, subfoveal, temporal, and nasal to the fovea, respectively. In comparison, the mean choroidal thickness in the control group was 274 ± 23 µm, 225 ± 17 µm, and 117 ± 17 µm, at the subfovea, 3 mm temporal to the fovea, and nasal to the fovea, respectively.Conclusions In PEX syndrome, there is choroidal thinning subfoveal, temporal, and nasal to the fovea on EDI-OCT. Decreased choroidal thickness, probably due to increased vascular resistance, and reduced blood flow, is seen in PEX syndrome.
    European journal of ophthalmology 04/2014; · 0.91 Impact Factor
  • Source
    European Journal of Pediatrics 02/2014; 173(2). · 1.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: : A 48-year-old male patient was operated for pterygium. During surgery, the autograft surface was lost because of sponge contact. Presumed epithelial face of the autograft subsequently was attached to the bare sclera with fibrin glue. It was observed that the center of the autograft was freely movable with sponge. This finding showed the inverse implantation of the autograft. Because the glue does not stick to intact corneal or conjunctival epithelium, free movement of the center of the autograft shows that the graft is inversely implanted.
    Eye & contact lens 01/2014;
  • Source
    American Journal of Ophthalmology 01/2014; 157(1):261. · 4.02 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective. To investigate the effects of topical and subconjunctival tigecycline on the prevention of corneal neovascularization. Materials and Methods. Following chemical burn, thirty-two rats were treated daily with topical instillation of 1 mg/mL tigecycline (group 1) or subconjunctival instillation of 1 mg/mL tigecycline (group 3) for 7 days. Control rats received topical (group 2) or subconjunctival (group 4) 0.9% saline. Digital photographs of the cornea were taken on the eighth day after treatment and analyzed to determine the percentage area of the cornea covered by neovascularization. Corneal sections were analyzed histopathologically. Results. The median percentages of corneal neovascularization in groups 1 and 3 were 48% (95% confidence interval (CI), 44.2-55.8%) and 33.5% (95% CI, 26.6-39.2%), respectively. The median percentages of corneal neovascularization of groups 1 and 3 were significantly lower than that of the control group (P = 0.03 and P < 0.001, resp.). Histologic examination of samples from groups 1 and 3 showed lower vascularity than that of control groups. Conclusion. Topical and subconjunctival administration of tigecycline seems to be showing promising therapeutic effects on the prevention of corneal neovascularization. Furthermore, subconjunctival administration of tigecycline is more potent than topical administration in the inhibition of corneal neovascularization.
    Journal of ophthalmology. 01/2014; 2014:452685.
  • Cornea 10/2013; · 1.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Purpose: To evaluate the ocular penetration of daptomycin, a new antibiotic agent targeted against Gram-positive organisms. Methods: Thirty-two New Zealand white rabbits were divided into 4 equal groups. One drop of 50 μL 1% daptomycin was administered to group 1. In group 2, 1 drop of 1% daptomycin was administered after the corneal epithelium was scraped. In group 3, 1 drop of 1% daptomycin was administered every 15 min for 1 h (keratitis protocol). In group 4, the keratitis protocol was applied after the corneal epithelium was scraped. In groups 1 and 2, aqueous humor samples were collected 30 min, 1 h, and 2 h after the single drop under general anesthesia. All the animals in groups 3 and 4 were humanely killed. Cornea, aqueous humor, and vitreous samples were collected 1 and 2 h after the last drop. Daptomycin concentrations were measured by high-performance liquid chromatography. Results: Each group comprised 8 rabbits. Daptomycin was not detected in the aqueous humor in groups 1 and 2. In group 3, the mean values at 1 h in the aqueous humor and cornea, respectively, were 1.90±0.15 μg/mL and 3.93±0.67 μg/g, and at 2 h were 1.71±0.42 μg/mL and 4.13±0.46 μg/g. In group 4, the mean values at 1 h were 5.19±0.50 μg/mL and 7.10±0.35 μg/g, and at 2 h were 4.96±0.47 μg/mL and 7.22±0.34 μg/g. Daptomycin was not detected in vitreous samples in groups 3 and 4. Conclusions: Single-drop administration does not yield a detectable daptomycin concentration in aqueous humor in neither nonscraped nor scraped group. In the multiple-drop regimen, daptomycin seems to penetrate well into the aqueous humor and cornea both in nonscraped and scraped groups. However, this concentration may not cover the minimum inhibitory concentration (MIC) of organisms such as Enterococcus fecalis.
    Journal of ocular pharmacology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics 09/2012; · 1.46 Impact Factor
  • Yasar Sakarya, Rabia Sakarya, Muammer Ozcimen
    Cornea 08/2012; · 1.75 Impact Factor
  • Rabia Sakarya, Yasar Sakarya, Muammer Ozcimen
    Journal of chemotherapy (Florence, Italy) 01/2012; 24(5):309. · 0.83 Impact Factor
  • Yasar Sakarya, Rabia Sakarya
    [Show abstract] [Hide abstract]
    ABSTRACT: To report a case of refractory atopic blepharoconjunctivitis (ABC) treated by using topical tacrolimus 0.03% dermatologic ointment. A 73-year-old man with ABC was refractory to topical corticosteroid treatment. Topical tacrolimus 0.03% dermatologic ointment (Protopic; Astellas Pharma) was applied into the conjunctival fornix twice each day. Dramatic improvement of patient's symptoms was observed during the first week of therapy. Tacrolimus ointment treatment continued for 12 months. No drug-induced conjunctival hyperemia, ocular surface staining, or other adverse changes were noted secondary to the use of the topical tacrolimus ointment. Topical tacrolimus 0.03% dermatologic ointment appears to be an effective treatment for ABC that is refractory to conventional therapy.
    Journal of ocular pharmacology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics 11/2011; 28(1):94-6. · 1.46 Impact Factor
  • Yasar Sakarya, Rabia Sakarya, Selcuk Kara
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate sensation change at nasal and superior conjunctival and corneal quadrants after pterygium surgery with conjunctival autograft. A prospective study was carried out in 14 patients. Seventeen eyes were operated for primary nasal pterygium. Sensation in nasal and superior conjunctival and corneal quadrants was measured with a Cochet-Bonnet aesthesiometer (CBA) before, and at 2 weeks, 1 month, and every month for 6 months after surgery. Preoperative and postoperative measurements were recorded and analyzed with Wilcoxon signed-rank test. The mean patient age was 53.5 years (range 44-68). All patients had nasal primary pterygium and completed the 6-month follow-up. The conjunctival autograft was correctly positioned and fixed in all eyes with fibrin glue. Mean ± SD sensations in conjunctival autograft were none (p<0.05) at 1 month, 4.28 ± 5.34 mm (p<0.05) at 2 months, 12.85 ± 2.67 mm (p<0.05) at 3 months, and returned to normal level, 23.57 ± 2.43 mm (p>0.05), at 4 months. Mean sensations in superior conjunctival area where the autograft was harvested were 11.42 ± 5.56 mm (p<0.05) at 1 month, and returned to normal level, 22.14 ± 2.67 mm (p>0.05), at 2 months. Mean sensations in nasal corneal area after surgery were 7.81 ± 4.06 mm (p<0.05) at 2 weeks, 26.42 ± 2.43 mm (p<0.05) at 1 month, and returned to normal level, 49.00 ± 3.38 mm (p>0.05), at 2 months. Mean sensations in superior corneal area did not change postoperatively. Anesthesia at first month and hypoesthesia at second and third month at conjunctival autograft was observed after pterygium surgery. Additionally, hypoesthesia was observed at nasal cornea and superior bulbar conjunctiva at the first month.
    European journal of ophthalmology 11/2011; 22 Suppl 7:S11-6. · 0.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Trabeculectomy is commonly conducted when medical therapy fails to control intraocular pressure (IOP). The success of trabeculectomy for the treatment of glaucoma depends on the wound-healing response at the subconjunctival filtering bleb site. Postoperative scar formation is a serious problem in this surgery. Current strategies to counteract scarring include local antimetabolite treatment, which is associated with severe side effects, limiting its application. Therefore, additional means to safely modulate wound healing are desirable. In ophthalmic surgery, fibrin glue is used mainly for sealing and hemostatics purpose. Fibrin glue coating of tenon face of conjunctiva, scleral surface, reverse face of scleral flap and scleral bed with insoluble fibrin glue can halt both ooze bleeding and vascular leakage. By retarding the first step of wound healing, less postoperative inflammation may occur. Additionally aqueous humor flows through a fibrin glue coated interface. Therefore, we hypothesize that fibrin glue coating of the surgical surfaces in trabeculectomy surgery may yield less subconjunctival fibrosis and more successful bleb. To the best of our knowledge, no basic research has yet been performed regarding fibrin glue coating for halting the vascular leakage and easing the aqueous drainage into subconjunctival space in glaucoma surgery.
    Medical Hypotheses 05/2011; 77(2):263-5. · 1.18 Impact Factor
  • Ophthalmic Genetics 03/2011; 32(1):64. · 1.07 Impact Factor